KRYS Kronos AI forecast
A 30-trading-day price forecast for Krystal Biotech Inc. (KRYS) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Krystal Biotech Inc. at $330.69 on 2026-12-08, +3.2% from the last close of $320.58 on 2026-10-27. Eight out of ten sampled paths end between $314.51 and $344.03, and 6 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of KRYS
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $326.04 | $321.49 | $334.58 |
| 2026-11-10 | $330.75 | $323.07 | $350.94 |
| 2026-11-17 | $332.46 | $321.33 | $363.95 |
| 2026-11-24 | $322.82 | $312.12 | $361.31 |
| 2026-12-01 | $322.89 | $315.29 | $354.53 |
| 2026-12-08 | $330.69 | $314.51 | $344.03 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for KRYS?
- Kronos AI's median forecast for KRYS is $330.69 in 30 trading days, +3.2% from the last close, with a 10–90% range of $314.51 to $344.03.
- Is the KRYS Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.